Publication Date

10-2020

Files

Download

Download Full Text (925 KB)

Abstract

Antimicrobial therapy is essential to treat cystic fibrosis (CF) lung infections. Empiric antimicrobial selection is generally based on previous culture information and, if available, an institution-specific antibiogram (ABGM). Most institutions antibiograms exclude cultures from individuals with cystic fibrosis, imposing challenges with empiric antimicrobial selection and monitoring susceptibility patterns over time. A cystic fibrosis-specific antibiogram may help drive population-specific antimicrobial selection and improve antimicrobial stewardship.

Disciplines

Infectious Disease | Pathology | Pharmacy and Pharmaceutical Sciences | Pulmonology

Notes

Presented at the 34th Annual North American Cystic Fibrosis Conference, in Philadelphia, PA, October 7-23, 2020.

Development and Interim Analysis of a Cystic Fibrosis-Specific Antibiogram

Share

COinS